+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Travel Vaccines Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030- Product Image
Travel Vaccines Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030- Product Image
New

Travel Vaccines Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030

  • PDF Icon

    Report

  • 187 Pages
  • May 2025
  • Region: Global, United States
  • 360iResearch™
  • ID: 6084080
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Travel Vaccines Market grew from USD 9.09 billion in 2024 to USD 10.01 billion in 2025. It is expected to continue growing at a CAGR of 10.10%, reaching USD 16.19 billion by 2030.

The global travel vaccines market is undergoing rapid transformation driven by evolving epidemiological threats, shifting traveler demographics, and breakthroughs in vaccine science. As international mobility rebounds post-pandemic, decision-makers face heightened expectations for safe, effective immunization strategies that address both endemic and emerging pathogens. Regulatory bodies are streamlining approval pathways, while public health agencies prioritize equitable access for travelers across diverse risk profiles. Meanwhile, manufacturers invest heavily in next-generation platforms-from mRNA and DNA modalities to novel adjuvants and delivery systems-to accelerate response times and enhance immunogenicity. These converging forces are reshaping market dynamics, demanding that stakeholders adopt agile planning, robust supply-chain resilience, and evidence-based advocacy. This executive summary distills the critical trends, policy impacts, segmentation insights, and strategic imperatives necessary for companies, regulators, and healthcare providers to navigate the complexities of the travel vaccines landscape with confidence.

Transformative Shifts Reshaping the Travel Vaccine Landscape

Recent years have ushered in transformative shifts that redefine how travel vaccines are developed, regulated, and delivered. First, technological breakthroughs in RNA and DNA vaccine platforms have shortened development timelines, enabling rapid response to novel threats. Simultaneously, regulatory harmonization initiatives across major markets are reducing duplication of clinical requirements, accelerating global rollout. Digital health tools-such as mobile immunization records and AI-driven adverse event monitoring-are enhancing both patient engagement and pharmacovigilance. Supply-chain diversification, including onshore fill-finish facilities and regional distribution hubs, is mitigating geopolitical risks and ensuring consistent product availability. Finally, personalized immunization strategies, leveraging immunoprofiling and epidemiological modeling, are shifting focus from one-size-fits-all dosing to risk-based booster recommendations. These convergent developments are not only improving public health outcomes but also redefining the competitive battleground for manufacturers and service providers.

Assessing the Cumulative Impact of U.S. Tariffs in 2025

In 2025, the introduction of new United States tariffs on selected vaccine imports has sent ripples through global supply chains and procurement strategies. By increasing duties on certain finished-dose shipments, import costs have risen, compelling manufacturers and distributors to reassess sourcing and pricing. Some firms have responded by near-shoring fill-finish operations to mitigate duty burdens, while others have renegotiated long-term supply contracts with strategic suppliers in duty-exempt jurisdictions. These adjustments have had downstream effects on government tenders and private sector procurement, where buyers are pushing for value-based pricing and total cost of ownership frameworks. Simultaneously, tariff-induced cost pressures have intensified collaborations between originator companies and contract manufacturing organizations, fostering investments in alternate delivery systems that promise reduced logistical complexity. Although immediate cost increases represent a headwind, they also incentivize innovation in local manufacturing capacity and public-private partnerships designed to secure vaccine availability and price stability over the long term.

Key Insights Derived from Market Segmentation

A granular view of market segmentation reveals nuanced opportunities and challenges across product, administration, end-user, demographic, technological, and production dimensions. Across vaccine type, the market is studied across inactivated vaccines including hepatitis A and rabies; live attenuated vaccines spanning rotavirus, typhoid, and yellow fever; RNA and DNA vaccines in the research and development phase; subunit, recombinant, polysaccharide, and conjugate vaccines covering hepatitis B and meningococcal; and toxoid vaccines such as diphtheria and tetanus. Based on route of administration, market segments encompass nasal spray vaccines under development, oral formulations targeting rotavirus and typhoid, and parenteral injections delivered via intramuscular and subcutaneous methods. In terms of traveler type, providers must tailor protocols for adventure tourists, business travelers, leisure travelers, student travelers (including exchange and international students), and individuals visiting friends and relatives. Age group segmentation differentiates dosing strategies for adults-both middle-aged and young adults-from pediatric cohorts subdivided into children and infants, as well as geriatric populations. End-user analysis spans ambulatory care settings, home care services, hospitals and clinics, and dedicated travel clinics. Technological advancements spotlight alternative delivery systems such as microneedle patches and wearable injectors alongside novel adjuvants like aluminum-free formulas and nanoparticle platforms. Finally, vaccine production technologies range from cell-based, egg-based, and plant-based methods, including tobacco plant-derived constructs, to recombinant DNA systems. Each segment offers distinct vectors for innovation, partnership, and market penetration.

Regional Dynamics Driving Travel Vaccine Adoption

Regional dynamics underscore significant variation in regulatory frameworks, infrastructure readiness, and traveler behavior. In the Americas, established public-private immunization programs, robust cold-chain networks, and centralized procurement models foster high-volume uptake and streamlined rollouts. Within Europe, Middle East & Africa, disparate national policies and regulatory divergence present both challenges and collaboration opportunities, while evolving travel corridors across the Schengen area and GCC nations generate complex demand patterns. The Asia-Pacific region is characterized by rapidly modernizing healthcare systems and an expanding middle class with growing discretionary travel budgets, driving increased demand for premium, technology-enhanced vaccines. Moreover, regional manufacturing hubs in India, China, and Singapore are attracting investment to serve both domestic and export markets, reinforcing global supply resilience.

Leading Companies Shaping the Travel Vaccine Ecosystem

The competitive landscape features global leaders and specialized innovators shaping strategic trajectories. Abbott Laboratories and AstraZeneca PLC leverage broad portfolios to integrate travel vaccines within comprehensive vaccine platforms. Bavarian Nordic A/S and Valneva SE focus on niche indications such as cholera and dengue, while Bharat Biotech Ltd., Serum Institute of India Pvt. Ltd., and Biological E Limited drive volume manufacturing for emerging market needs. Bio-Manguinhos and Bio-Med (P) Limited serve as pivotal regional suppliers in Latin America and South Asia, respectively. Cadila Pharmaceuticals Limited and CSL Limited are expanding R&D into novel adjuvant technologies. Dano Vaccines & Biologicals Private Limited and Dynavax Technologies Corporation explore next-generation immune-modulators. Emergent BioSolutions Inc. and GlaxoSmithKline PLC maintain robust travel vaccine pipelines complemented by strategic partnerships. Incepta Pharmaceuticals Ltd. and Indian Immunologicals Ltd. harness local expertise to optimize cost-effective production. Johnson & Johnson Services, Inc., Merck & Co., Inc., Novartis AG, Pfizer Inc., Sanofi S.A., Shenzhen Kangtai Biological Products Co., Ltd., Takeda Pharmaceutical Company Limited, and Walvax Biotechnology Co., Ltd. reinforce their global reach through alliances and capacity expansions. Across these players, trends in M&A, licensing deals, and co-development agreements underscore an industry-wide pivot toward integrated solutions that unify platform technologies, delivery innovations, and expanded geographic coverage.

Actionable Recommendations for Industry Leadership

Industry leaders must take proactive steps to secure competitive advantage and drive sustainable growth:
  • Expand localized manufacturing capacity and strategic partnerships to mitigate tariff exposure and address regional supply gaps.
  • Integrate digital health tools-such as immunization tracking apps, AI-based demand forecasting, and telehealth platforms-to enhance patient engagement and streamline distribution.
  • Prioritize next-generation platforms (e.g., RNA, DNA, nanoparticle adjuvants) while fostering cross-sector collaborations between biotech innovators and large-scale manufacturers.
  • Develop adaptive pricing models that reflect total cost of ownership, aligning incentives for payors, travel clinics, and end-users to improve access and affordability.
  • Strengthen regulatory intelligence functions to navigate evolving harmonization efforts and accelerate global launch sequences through early engagement with health authorities.
By embracing these measures, organizations can transform current headwinds into catalysts for resilience and market leadership.

Conclusion: Positioning for Future Resilience in Travel Vaccines

As the travel vaccines market enters a new phase of complexity and opportunity, stakeholders must stay ahead of technological, regulatory, and geopolitical shifts. Innovations in vaccine platforms and alternative delivery systems promise to redefine immunization protocols, but require coordinated investment, regulatory alignment, and robust supply-chain design. Regional strategies must account for diverse healthcare infrastructures and traveler demographics, leveraging local partnerships to ensure equitable access. Meanwhile, tariff dynamics underscore the importance of flexible manufacturing footprints and value-based pricing models that balance cost recovery with public health imperatives. Ultimately, success will hinge on the ability to integrate data-driven insights, digital health enablers, and collaborative frameworks across the value chain, forging more resilient and responsive immunization ecosystems at every stage of the traveler journey.

Market Segmentation & Coverage

This research report categorizes the Travel Vaccines Market to forecast the revenues and analyze trends in each of the following sub-segmentations:

  • Inactivated Vaccines
    • Hepatitis A Vaccine
    • Rabies Vaccine
  • Live Attenuated Vaccines
    • Rotavirus Vaccine
    • Typhoid Vaccine
    • Yellow Fever Vaccine
  • RNA and DNA Vaccines
    • Research and Development Phase Vaccines
  • Subunit, Recombinant, Polysaccharide, and Conjugate Vaccines
    • Hepatitis B Vaccine
    • Meningococcal Vaccine
  • Toxoid Vaccines
    • Diphtheria Vaccine
    • Tetanus Vaccine
  • Nasal Spray Vaccines
    • Research and Development Phase Vaccines
  • Oral Vaccines
    • Rotavirus Vaccine
    • Typhoid Vaccine
  • Parenteral Vaccines
    • Intramuscular Injections
    • Subcutaneous Injections
  • Adventure Tourists
  • Business Travelers
  • Leisure Travelers
  • Student Travelers
    • Exchange Students
    • International Students
  • VFR Travelers (Visiting Friends and Relatives)
  • Adult Vaccines
    • Middle-Aged
    • Young Adults
  • Geriatric Vaccines
  • Pediatric Vaccines
    • Children Age Group
    • Infant Age Group
  • Ambulatory Care Setting
  • Home Care
  • Hospitals and Clinics
  • Travel Clinics
  • Alternative Delivery Systems
    • Microneedle Patches
    • Wearable Delivery Systems
  • Novel Adjuvants
    • Aluminum-Free Adjuvants
    • Nanoparticle-Based Adjuvants
  • Cell-Based Production
  • Egg-Based Production
  • Plant-Based Production
    • Tobacco Plant-Based Vaccines
  • Recombinant DNA Technology

This research report categorizes the Travel Vaccines Market to forecast the revenues and analyze trends in each of the following sub-regions:

  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

This research report categorizes the Travel Vaccines Market to delves into recent significant developments and analyze trends in each of the following companies:

  • Abbott Laboratories
  • AstraZeneca PLC
  • Bavarian Nordic A/S
  • Bharat Biotech Ltd.
  • Bio-Manguinhos
  • Bio-Med (P) Limited
  • Biological E Limited
  • Cadila Pharmaceuticals Limited
  • CSL Limited
  • Dano Vaccines & Biologicals Private Limited
  • Dynavax Technologies Corporation
  • Emergent BioSolutions Inc.
  • GlaxoSmithKline PLC
  • Incepta Pharmaceuticals Ltd.
  • Indian Immunologicals Ltd.
  • Johnson & Johnson Services, Inc
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Serum Institute of India Pvt. Ltd.
  • Shenzhen Kangtai Biological Products Co., Ltd.
  • Takeda Pharmaceutical Company Limited
  • Valneva SE
  • Walvax Biotechnology Co., Ltd.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Travel Vaccines Market, by Vaccine Type
8.1. Introduction
8.2. Inactivated Vaccines
8.2.1. Hepatitis A Vaccine
8.2.2. Rabies Vaccine
8.3. Live Attenuated Vaccines
8.3.1. Rotavirus Vaccine
8.3.2. Typhoid Vaccine
8.3.3. Yellow Fever Vaccine
8.4. RNA and DNA Vaccines
8.4.1. Research and Development Phase Vaccines
8.5. Subunit, Recombinant, Polysaccharide, and Conjugate Vaccines
8.5.1. Hepatitis B Vaccine
8.5.2. Meningococcal Vaccine
8.6. Toxoid Vaccines
8.6.1. Diphtheria Vaccine
8.6.2. Tetanus Vaccine
9. Travel Vaccines Market, by Route of Administration
9.1. Introduction
9.2. Nasal Spray Vaccines
9.2.1. Research and Development Phase Vaccines
9.3. Oral Vaccines
9.3.1. Rotavirus Vaccine
9.3.2. Typhoid Vaccine
9.4. Parenteral Vaccines
9.4.1. Intramuscular Injections
9.4.2. Subcutaneous Injections
10. Travel Vaccines Market, by Traveler Type
10.1. Introduction
10.2. Adventure Tourists
10.3. Business Travelers
10.4. Leisure Travelers
10.5. Student Travelers
10.5.1. Exchange Students
10.5.2. International Students
10.6. VFR Travelers (Visiting Friends and Relatives)
11. Travel Vaccines Market, by Age Group
11.1. Introduction
11.2. Adult Vaccines
11.2.1. Middle-Aged
11.2.2. Young Adults
11.3. Geriatric Vaccines
11.4. Pediatric Vaccines
11.4.1. Children Age Group
11.4.2. Infant Age Group
12. Travel Vaccines Market, by End Users
12.1. Introduction
12.2. Ambulatory Care Setting
12.3. Home Care
12.4. Hospitals and Clinics
12.5. Travel Clinics
13. Travel Vaccines Market, by Technological Advancements
13.1. Introduction
13.2. Alternative Delivery Systems
13.2.1. Microneedle Patches
13.2.2. Wearable Delivery Systems
13.3. Novel Adjuvants
13.3.1. Aluminum-Free Adjuvants
13.3.2. Nanoparticle-Based Adjuvants
14. Travel Vaccines Market, by Vaccine Production Technologies
14.1. Introduction
14.2. Cell-Based Production
14.3. Egg-Based Production
14.4. Plant-Based Production
14.4.1. Tobacco Plant-Based Vaccines
14.5. Recombinant DNA Technology
15. Americas Travel Vaccines Market
15.1. Introduction
15.2. Argentina
15.3. Brazil
15.4. Canada
15.5. Mexico
15.6. United States
16. Asia-Pacific Travel Vaccines Market
16.1. Introduction
16.2. Australia
16.3. China
16.4. India
16.5. Indonesia
16.6. Japan
16.7. Malaysia
16.8. Philippines
16.9. Singapore
16.10. South Korea
16.11. Taiwan
16.12. Thailand
16.13. Vietnam
17. Europe, Middle East & Africa Travel Vaccines Market
17.1. Introduction
17.2. Denmark
17.3. Egypt
17.4. Finland
17.5. France
17.6. Germany
17.7. Israel
17.8. Italy
17.9. Netherlands
17.10. Nigeria
17.11. Norway
17.12. Poland
17.13. Qatar
17.14. Russia
17.15. Saudi Arabia
17.16. South Africa
17.17. Spain
17.18. Sweden
17.19. Switzerland
17.20. Turkey
17.21. United Arab Emirates
17.22. United Kingdom
18. Competitive Landscape
18.1. Market Share Analysis, 2024
18.2. FPNV Positioning Matrix, 2024
18.3. Competitive Analysis
18.3.1. Abbott Laboratories
18.3.2. AstraZeneca PLC
18.3.3. Bavarian Nordic A/S
18.3.4. Bharat Biotech Ltd.
18.3.5. Bio-Manguinhos
18.3.6. Bio-Med (P) Limited
18.3.7. Biological E Limited
18.3.8. Cadila Pharmaceuticals Limited
18.3.9. CSL Limited
18.3.10. Dano Vaccines & Biologicals Private Limited
18.3.11. Dynavax Technologies Corporation
18.3.12. Emergent BioSolutions Inc.
18.3.13. GlaxoSmithKline PLC
18.3.14. Incepta Pharmaceuticals Ltd.
18.3.15. Indian Immunologicals Ltd.
18.3.16. Johnson & Johnson Services, Inc
18.3.17. Merck & Co., Inc.
18.3.18. Novartis AG
18.3.19. Pfizer Inc.
18.3.20. Sanofi S.A.
18.3.21. Serum Institute of India Pvt. Ltd.
18.3.22. Shenzhen Kangtai Biological Products Co., Ltd.
18.3.23. Takeda Pharmaceutical Company Limited
18.3.24. Valneva SE
18.3.25. Walvax Biotechnology Co., Ltd.
19. ResearchAI
20. ResearchStatistics
21. ResearchContacts
22. ResearchArticles
23. Appendix
List of Figures
FIGURE 1. TRAVEL VACCINES MARKET MULTI-CURRENCY
FIGURE 2. TRAVEL VACCINES MARKET MULTI-LANGUAGE
FIGURE 3. TRAVEL VACCINES MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL TRAVEL VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL TRAVEL VACCINES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL TRAVEL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL TRAVEL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL TRAVEL VACCINES MARKET SIZE, BY TRAVELER TYPE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL TRAVEL VACCINES MARKET SIZE, BY TRAVELER TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2024 VS 2030 (%)
FIGURE 14. GLOBAL TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL TRAVEL VACCINES MARKET SIZE, BY END USERS, 2024 VS 2030 (%)
FIGURE 16. GLOBAL TRAVEL VACCINES MARKET SIZE, BY END USERS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL TRAVEL VACCINES MARKET SIZE, BY TECHNOLOGICAL ADVANCEMENTS, 2024 VS 2030 (%)
FIGURE 18. GLOBAL TRAVEL VACCINES MARKET SIZE, BY TECHNOLOGICAL ADVANCEMENTS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. GLOBAL TRAVEL VACCINES MARKET SIZE, BY VACCINE PRODUCTION TECHNOLOGIES, 2024 VS 2030 (%)
FIGURE 20. GLOBAL TRAVEL VACCINES MARKET SIZE, BY VACCINE PRODUCTION TECHNOLOGIES, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. AMERICAS TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. AMERICAS TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. UNITED STATES TRAVEL VACCINES MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 24. UNITED STATES TRAVEL VACCINES MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ASIA-PACIFIC TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. ASIA-PACIFIC TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. EUROPE, MIDDLE EAST & AFRICA TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 28. EUROPE, MIDDLE EAST & AFRICA TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 29. TRAVEL VACCINES MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 30. TRAVEL VACCINES MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. TRAVEL VACCINES MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL TRAVEL VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL TRAVEL VACCINES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL TRAVEL VACCINES MARKET SIZE, BY INACTIVATED VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL TRAVEL VACCINES MARKET SIZE, BY HEPATITIS A VACCINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL TRAVEL VACCINES MARKET SIZE, BY RABIES VACCINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL TRAVEL VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL TRAVEL VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL TRAVEL VACCINES MARKET SIZE, BY ROTAVIRUS VACCINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL TRAVEL VACCINES MARKET SIZE, BY TYPHOID VACCINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL TRAVEL VACCINES MARKET SIZE, BY YELLOW FEVER VACCINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL TRAVEL VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINES, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL TRAVEL VACCINES MARKET SIZE, BY RNA AND DNA VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL TRAVEL VACCINES MARKET SIZE, BY RESEARCH AND DEVELOPMENT PHASE VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL TRAVEL VACCINES MARKET SIZE, BY RNA AND DNA VACCINES, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL TRAVEL VACCINES MARKET SIZE, BY SUBUNIT, RECOMBINANT, POLYSACCHARIDE, AND CONJUGATE VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL TRAVEL VACCINES MARKET SIZE, BY HEPATITIS B VACCINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL TRAVEL VACCINES MARKET SIZE, BY MENINGOCOCCAL VACCINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL TRAVEL VACCINES MARKET SIZE, BY SUBUNIT, RECOMBINANT, POLYSACCHARIDE, AND CONJUGATE VACCINES, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL TRAVEL VACCINES MARKET SIZE, BY TOXOID VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL TRAVEL VACCINES MARKET SIZE, BY DIPHTHERIA VACCINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL TRAVEL VACCINES MARKET SIZE, BY TETANUS VACCINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL TRAVEL VACCINES MARKET SIZE, BY TOXOID VACCINES, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL TRAVEL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL TRAVEL VACCINES MARKET SIZE, BY NASAL SPRAY VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL TRAVEL VACCINES MARKET SIZE, BY RESEARCH AND DEVELOPMENT PHASE VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL TRAVEL VACCINES MARKET SIZE, BY NASAL SPRAY VACCINES, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL TRAVEL VACCINES MARKET SIZE, BY ORAL VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL TRAVEL VACCINES MARKET SIZE, BY ROTAVIRUS VACCINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL TRAVEL VACCINES MARKET SIZE, BY TYPHOID VACCINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL TRAVEL VACCINES MARKET SIZE, BY ORAL VACCINES, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL TRAVEL VACCINES MARKET SIZE, BY PARENTERAL VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL TRAVEL VACCINES MARKET SIZE, BY INTRAMUSCULAR INJECTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL TRAVEL VACCINES MARKET SIZE, BY SUBCUTANEOUS INJECTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL TRAVEL VACCINES MARKET SIZE, BY PARENTERAL VACCINES, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL TRAVEL VACCINES MARKET SIZE, BY TRAVELER TYPE, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL TRAVEL VACCINES MARKET SIZE, BY ADVENTURE TOURISTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL TRAVEL VACCINES MARKET SIZE, BY BUSINESS TRAVELERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL TRAVEL VACCINES MARKET SIZE, BY LEISURE TRAVELERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL TRAVEL VACCINES MARKET SIZE, BY STUDENT TRAVELERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL TRAVEL VACCINES MARKET SIZE, BY EXCHANGE STUDENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL TRAVEL VACCINES MARKET SIZE, BY INTERNATIONAL STUDENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL TRAVEL VACCINES MARKET SIZE, BY STUDENT TRAVELERS, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL TRAVEL VACCINES MARKET SIZE, BY VFR TRAVELERS (VISITING FRIENDS AND RELATIVES), BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL TRAVEL VACCINES MARKET SIZE, BY ADULT VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL TRAVEL VACCINES MARKET SIZE, BY MIDDLE-AGED, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL TRAVEL VACCINES MARKET SIZE, BY YOUNG ADULTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL TRAVEL VACCINES MARKET SIZE, BY ADULT VACCINES, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL TRAVEL VACCINES MARKET SIZE, BY GERIATRIC VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL TRAVEL VACCINES MARKET SIZE, BY PEDIATRIC VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL TRAVEL VACCINES MARKET SIZE, BY CHILDREN AGE GROUP, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL TRAVEL VACCINES MARKET SIZE, BY INFANT AGE GROUP, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL TRAVEL VACCINES MARKET SIZE, BY PEDIATRIC VACCINES, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL TRAVEL VACCINES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL TRAVEL VACCINES MARKET SIZE, BY AMBULATORY CARE SETTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL TRAVEL VACCINES MARKET SIZE, BY HOME CARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL TRAVEL VACCINES MARKET SIZE, BY HOSPITALS AND CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL TRAVEL VACCINES MARKET SIZE, BY TRAVEL CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 63. GLOBAL TRAVEL VACCINES MARKET SIZE, BY TECHNOLOGICAL ADVANCEMENTS, 2018-2030 (USD MILLION)
TABLE 64. GLOBAL TRAVEL VACCINES MARKET SIZE, BY ALTERNATIVE DELIVERY SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 65. GLOBAL TRAVEL VACCINES MARKET SIZE, BY MICRONEEDLE PATCHES, BY REGION, 2018-2030 (USD MILLION)
TABLE 66. GLOBAL TRAVEL VACCINES MARKET SIZE, BY WEARABLE DELIVERY SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 67. GLOBAL TRAVEL VACCINES MARKET SIZE, BY ALTERNATIVE DELIVERY SYSTEMS, 2018-2030 (USD MILLION)
TABLE 68. GLOBAL TRAVEL VACCINES MARKET SIZE, BY NOVEL ADJUVANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 69. GLOBAL TRAVEL VACCINES MARKET SIZE, BY ALUMINUM-FREE ADJUVANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 70. GLOBAL TRAVEL VACCINES MARKET SIZE, BY NANOPARTICLE-BASED ADJUVANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 71. GLOBAL TRAVEL VACCINES MARKET SIZE, BY NOVEL ADJUVANTS, 2018-2030 (USD MILLION)
TABLE 72. GLOBAL TRAVEL VACCINES MARKET SIZE, BY VACCINE PRODUCTION TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 73. GLOBAL TRAVEL VACCINES MARKET SIZE, BY CELL-BASED PRODUCTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 74. GLOBAL TRAVEL VACCINES MARKET SIZE, BY EGG-BASED PRODUCTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 75. GLOBAL TRAVEL VACCINES MARKET SIZE, BY PLANT-BASED PRODUCTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 76. GLOBAL TRAVEL VACCINES MARKET SIZE, BY TOBACCO PLANT-BASED VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 77. GLOBAL TRAVEL VACCINES MARKET SIZE, BY PLANT-BASED PRODUCTION, 2018-2030 (USD MILLION)
TABLE 78. GLOBAL TRAVEL VACCINES MARKET SIZE, BY RECOMBINANT DNA TECHNOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 79. AMERICAS TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 80. AMERICAS TRAVEL VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
TABLE 81. AMERICAS TRAVEL VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINES, 2018-2030 (USD MILLION)
TABLE 82. AMERICAS TRAVEL VACCINES MARKET SIZE, BY RNA AND DNA VACCINES, 2018-2030 (USD MILLION)
TABLE 83. AMERICAS TRAVEL VACCINES MARKET SIZE, BY SUBUNIT, RECOMBINANT, POLYSACCHARIDE, AND CONJUGATE VACCINES, 2018-2030 (USD MILLION)
TABLE 84. AMERICAS TRAVEL VACCINES MARKET SIZE, BY TOXOID VACCINES, 2018-2030 (USD MILLION)
TABLE 85. AMERICAS TRAVEL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 86. AMERICAS TRAVEL VACCINES MARKET SIZE, BY NASAL SPRAY VACCINES, 2018-2030 (USD MILLION)
TABLE 87. AMERICAS TRAVEL VACCINES MARKET SIZE, BY ORAL VACCINES, 2018-2030 (USD MILLION)
TABLE 88. AMERICAS TRAVEL VACCINES MARKET SIZE, BY PARENTERAL VACCINES, 2018-2030 (USD MILLION)
TABLE 89. AMERICAS TRAVEL VACCINES MARKET SIZE, BY TRAVELER TYPE, 2018-2030 (USD MILLION)
TABLE 90. AMERICAS TRAVEL VACCINES MARKET SIZE, BY STUDENT TRAVELERS, 2018-2030 (USD MILLION)
TABLE 91. AMERICAS TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 92. AMERICAS TRAVEL VACCINES MARKET SIZE, BY ADULT VACCINES, 2018-2030 (USD MILLION)
TABLE 93. AMERICAS TRAVEL VACCINES MARKET SIZE, BY PEDIATRIC VACCINES, 2018-2030 (USD MILLION)
TABLE 94. AMERICAS TRAVEL VACCINES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 95. AMERICAS TRAVEL VACCINES MARKET SIZE, BY TECHNOLOGICAL ADVANCEMENTS, 2018-2030 (USD MILLION)
TABLE 96. AMERICAS TRAVEL VACCINES MARKET SIZE, BY ALTERNATIVE DELIVERY SYSTEMS, 2018-2030 (USD MILLION)
TABLE 97. AMERICAS TRAVEL VACCINES MARKET SIZE, BY NOVEL ADJUVANTS, 2018-2030 (USD MILLION)
TABLE 98. AMERICAS TRAVEL VACCINES MARKET SIZE, BY VACCINE PRODUCTION TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 99. AMERICAS TRAVEL VACCINES MARKET SIZE, BY PLANT-BASED PRODUCTION, 2018-2030 (USD MILLION)
TABLE 100. AMERICAS TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 101. ARGENTINA TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 102. ARGENTINA TRAVEL VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
TABLE 103. ARGENTINA TRAVEL VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINES, 2018-2030 (USD MILLION)
TABLE 104. ARGENTINA TRAVEL VACCINES MARKET SIZE, BY RNA AND DNA VACCINES, 2018-2030 (USD MILLION)
TABLE 105. ARGENTINA TRAVEL VACCINES MARKET SIZE, BY SUBUNIT, RECOMBINANT, POLYSACCHARIDE, AND CONJUGATE VACCINES, 2018-2030 (USD MILLION)
TABLE 106. ARGENTINA TRAVEL VACCINES MARKET SIZE, BY TOXOID VACCINES, 2018-2030 (USD MILLION)
TABLE 107. ARGENTINA TRAVEL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 108. ARGENTINA TRAVEL VACCINES MARKET SIZE, BY NASAL SPRAY VACCINES, 2018-2030 (USD MILLION)
TABLE 109. ARGENTINA TRAVEL VACCINES MARKET SIZE, BY ORAL VACCINES, 2018-2030 (USD MILLION)
TABLE 110. ARGENTINA TRAVEL VACCINES MARKET SIZE, BY PARENTERAL VACCINES, 2018-2030 (USD MILLION)
TABLE 111. ARGENTINA TRAVEL VACCINES MARKET SIZE, BY TRAVELER TYPE, 2018-2030 (USD MILLION)
TABLE 112. ARGENTINA TRAVEL VACCINES MARKET SIZE, BY STUDENT TRAVELERS, 2018-2030 (USD MILLION)
TABLE 113. ARGENTINA TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 114. ARGENTINA TRAVEL VACCINES MARKET SIZE, BY ADULT VACCINES, 2018-2030 (USD MILLION)
TABLE 115. ARGENTINA TRAVEL VACCINES MARKET SIZE, BY PEDIATRIC VACCINES, 2018-2030 (USD MILLION)
TABLE 116. ARGENTINA TRAVEL VACCINES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 117. ARGENTINA TRAVEL VACCINES MARKET SIZE, BY TECHNOLOGICAL ADVANCEMENTS, 2018-2030 (USD MILLION)
TABLE 118. ARGENTINA TRAVEL VACCINES MARKET SIZE, BY ALTERNATIVE DELIVERY SYSTEMS, 2018-2030 (USD MILLION)
TABLE 119. ARGENTINA TRAVEL VACCINES MARKET SIZE, BY NOVEL ADJUVANTS, 2018-2030 (USD MILLION)
TABLE 120. ARGENTINA TRAVEL VACCINES MARKET SIZE, BY VACCINE PRODUCTION TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 121. ARGENTINA TRAVEL VACCINES MARKET SIZE, BY PLANT-BASED PRODUCTION, 2018-2030 (USD MILLION)
TABLE 122. BRAZIL TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 123. BRAZIL TRAVEL VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
TABLE 124. BRAZIL TRAVEL VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINES, 2018-2030 (USD MILLION)
TABLE 125. BRAZIL TRAVEL VACCINES MARKET SIZE, BY RNA AND DNA VACCINES, 2018-2030 (USD MILLION)
TABLE 126. BRAZIL TRAVEL VACCINES MARKET SIZE, BY SUBUNIT, RECOMBINANT, POLYSACCHARIDE, AND CONJUGATE VACCINES, 2018-2030 (USD MILLION)
TABLE 127. BRAZIL TRAVEL VACCINES MARKET SIZE, BY TOXOID VACCINES, 2018-2030 (USD MILLION)
TABLE 128. BRAZIL TRAVEL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 129. BRAZIL TRAVEL VACCINES MARKET SIZE, BY NASAL SPRAY VACCINES, 2018-2030 (USD MILLION)
TABLE 130. BRAZIL TRAVEL VACCINES MARKET SIZE, BY ORAL VACCINES, 2018-2030 (USD MILLION)
TABLE 131. BRAZIL TRAVEL VACCINES MARKET SIZE, BY PARENTERAL VACCINES, 2018-2030 (USD MILLION)
TABLE 132. BRAZIL TRAVEL VACCINES MARKET SIZE, BY TRAVELER TYPE, 2018-2030 (USD MILLION)
TABLE 133. BRAZIL TRAVEL VACCINES MARKET SIZE, BY STUDENT TRAVELERS, 2018-2030 (USD MILLION)
TABLE 134. BRAZIL TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 135. BRAZIL TRAVEL VACCINES MARKET SIZE, BY ADULT VACCINES, 2018-2030 (USD MILLION)
TABLE 136. BRAZIL TRAVEL VACCINES MARKET SIZE, BY PEDIATRIC VACCINES, 2018-2030 (USD MILLION)
TABLE 137. BRAZIL TRAVEL VACCINES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 138. BRAZIL TRAVEL VACCINES MARKET SIZE, BY TECHNOLOGICAL ADVANCEMENTS, 2018-2030 (USD MILLION)
TABLE 139. BRAZIL TRAVEL VACCINES MARKET SIZE, BY ALTERNATIVE DELIVERY SYSTEMS, 2018-2030 (USD MILLION)
TABLE 140. BRAZIL TRAVEL VACCINES MARKET SIZE, BY NOVEL ADJUVANTS, 2018-2030 (USD MILLION)
TABLE 141. BRAZIL TRAVEL VACCINES MARKET SIZE, BY VACCINE PRODUCTION TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 142. BRAZIL TRAVEL VACCINES MARKET SIZE, BY PLANT-BASED PRODUCTION, 2018-2030 (USD MILLION)
TABLE 143. CANADA TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 144. CANADA TRAVEL VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
TABLE 145. CANADA TRAVEL VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINES, 2018-2030 (USD MILLION)
TABLE 146. CANADA TRAVEL VACCINES MARKET SIZE, BY RNA AND DNA VACCINES, 2018-2030 (USD MILLION)
TABLE 147. CANADA TRAVEL VACCINES MARKET SIZE, BY SUBUNIT, RECOMBINANT, POLYSACCHARIDE, AND CONJUGATE VACCINES, 2018-2030 (USD MILLION)
TABLE 148. CANADA TRAVEL VACCINES MARKET SIZE, BY TOXOID VACCINES, 2018-2030 (USD MILLION)
TABLE 149. CANADA TRAVEL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 150. CANADA TRAVEL VACCINES MARKET SIZE, BY NASAL SPRAY VACCINES, 2018-2030 (USD MILLION)
TABLE 151. CANADA TRAVEL VACCINES MARKET SIZE, BY ORAL VACCINES, 2018-2030 (USD MILLION)
TABLE 152. CANADA TRAVEL VACCINES MARKET SIZE, BY PARENTERAL VACCINES, 2018-2030 (USD MILLION)
TABLE 153. CANADA TRAVEL VACCINES MARKET SIZE, BY TRAVELER TYPE, 2018-2030 (USD MILLION)
TABLE 154. CANADA TRAVEL VACCINES MARKET SIZE, BY STUDENT TRAVELERS, 2018-2030 (USD MILLION)
TABLE 155. CANADA TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 156. CANADA TRAVEL VACCINES MARKET SIZE, BY ADULT VACCINES, 2018-2030 (USD MILLION)
TABLE 157. CANADA TRAVEL VACCINES MARKET SIZE, BY PEDIATRIC VACCINES, 2018-2030 (USD MILLION)
TABLE 158. CANADA TRAVEL VACCINES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 159. CANADA TRAVEL VACCINES MARKET SIZE, BY TECHNOLOGICAL ADVANCEMENTS, 2018-2030 (USD MILLION)
TABLE 160. CANADA TRAVEL VACCINES MARKET SIZE, BY ALTERNATIVE DELIVERY SYSTEMS, 2018-2030 (USD MILLION)
TABLE 161. CANADA TRAVEL VACCINES MARKET SIZE, BY NOVEL ADJUVANTS, 2018-2030 (USD MILLION)
TABLE 162. CANADA TRAVEL VACCINES MARKET SIZE, BY VACCINE PRODUCTION TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 163. CANADA TRAVEL VACCINES MARKET SIZE, BY PLANT-BASED PRODUCTION, 2018-2030 (USD MILLION)
TABLE 164. MEXICO TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 165. MEXICO TRAVEL VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
TABLE 166. MEXICO TRAVEL VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINES, 2018-2030 (USD MILLION)
TABLE 167. MEXICO TRAVEL VACCINES MARKET SIZE, BY RNA AND DNA VACCINES, 2018-2030 (USD MILLION)
TABLE 168. MEXICO TRAVEL VACCINES MARKET SIZE, BY SUBUNIT, RECOMBINANT, POLYSACCHARIDE, AND CONJUGATE VACCINES, 2018-2030 (USD MILLION)
TABLE 169. MEXICO TRAVEL VACCINES MARKET SIZE, BY TOXOID VACCINES, 2018-2030 (USD MILLION)
TABLE 170. MEXICO TRAVEL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 171. MEXICO TRAVEL VACCINES MARKET SIZE, BY NASAL SPRAY VACCINES, 2018-2030 (USD MILLION)
TABLE 172. MEXICO TRAVEL VACCINES MARKET SIZE, BY ORAL VACCINES, 2018-2030 (USD MILLION)
TABLE 173. MEXICO TRAVEL VACCINES MARKET SIZE, BY PARENTERAL VACCINES, 2018-2030 (USD MILLION)
TABLE 174. MEXICO TRAVEL VACCINES MARKET SIZE, BY TRAVELER TYPE, 2018-2030 (USD MILLION)
TABLE 175. MEXICO TRAVEL VACCINES MARKET SIZE, BY STUDENT TRAVELERS, 2018-2030 (USD MILLION)
TABLE 176. MEXICO TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 177. MEXICO TRAVEL VACCINES MARKET SIZE, BY ADULT VACCINES, 2018-2030 (USD MILLION)
TABLE 178. MEXICO TRAVEL VACCINES MARKET SIZE, BY PEDIATRIC VACCINES, 2018-2030 (USD MILLION)
TABLE 179. MEXICO TRAVEL VACCINES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 180. MEXICO TRAVEL VACCINES MARKET SIZE, BY TECHNOLOGICAL ADVANCEMENTS, 2018-2030 (USD MILLION)
TABLE 181. MEXICO TRAVEL VACCINES MARKET SIZE, BY ALTERNATIVE DELIVERY SYSTEMS, 2018-2030 (USD MILLION)
TABLE 182. MEXICO TRAVEL VACCINES MARKET SIZE, BY NOVEL ADJUVANTS, 2018-2030 (USD MILLION)
TABLE 183. MEXICO TRAVEL VACCINES MARKET SIZE, BY VACCINE PRODUCTION TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 184. MEXICO TRAVEL VACCINES MARKET SIZE, BY PLANT-BASED PRODUCTION, 2018-2030 (USD MILLION)
TABLE 185. UNITED STATES TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 186. UNITED STATES TRAVEL VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
TABLE 187. UNITED STATES TRAVEL VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINES, 2018-2030 (USD MILLION)
TABLE 188. UNITED STATES TRAVEL VACCINES MARKET SIZE, BY RNA AND DNA VACCINES, 2018-2030 (USD MILLION)
TABLE 189. UNITED STATES TRAVEL VACCINES MARKET SIZE, BY SUBUNIT, RECOMBINANT, POLYSACCHARIDE, AND CONJUGATE VACCINES, 2018-2030 (USD MILLION)
TABLE 190. UNITED STATES TRAVEL VACCINES MARKET SIZE, BY TOXOID VACCINES, 2018-2030 (USD MILLION)
TABLE 191. UNITED STATES TRAVEL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 192. UNITED STATES TRAVEL VACCINES MARKET SIZE, BY NASAL SPRAY VACCINES, 2018-2030 (USD MILLION)
TABLE 193. UNITED STATES TRAVEL VACCINES MARKET SIZE, BY ORAL VACCINES, 2018-2030 (USD MILLION)
TABLE 194. UNITED STATES TRAVEL VACCINES MARKET SIZE, BY PARENTERAL VACCINES, 2018-2030 (USD MILLION)
TABLE 195. UNITED STATES TRAVEL VACCINES MARKET SIZE, BY TRAVELER TYPE, 2018-2030 (USD MILLION)
TABLE 196. UNITED STATES TRAVEL VACCINES MARKET SIZE, BY STUDENT TRAVELERS, 2018-2030 (USD MILLION)
TABLE 197. UNITED STATES TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 198. UNITED STATES TRAVEL VACCINES MARKET SIZE, BY ADULT VACCINES, 2018-2030 (USD MILLION)
TABLE 199. UNITED STATES TRAVEL VACCINES MARKET SIZE, BY PEDIATRIC VACCINES, 2018-2030 (USD MILLION)
TABLE 200. UNITED STATES TRAVEL VACCINES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 201. UNITED STATES TRAVEL VACCINES MARKET SIZE, BY TECHNOLOGICAL ADVANCEMENTS, 2018-2030 (USD MILLION)
TABLE 202. UNITED STATES TRAVEL VACCINES MARKET SIZE, BY ALTERNATIVE DELIVERY SYSTEMS, 2018-2030 (USD MILLION)
TABLE 203. UNITED STATES TRAVEL VACCINES MARKET SIZE, BY NOVEL ADJUVANTS, 2018-2030 (USD MILLION)
TABLE 204. UNITED STATES TRAVEL VACCINES MARKET SIZE, BY VACCINE PRODUCTION TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 205. UNITED STATES TRAVEL VACCINES MARKET SIZE, BY PLANT-BASED PRODUCTION, 2018-2030 (USD MILLION)
TABLE 206. UNITED STATES TRAVEL VACCINES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 207. ASIA-PACIFIC TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 208. ASIA-PACIFIC TRAVEL VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
TABLE 209. ASIA-PACIFIC TRAVEL VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINES, 2018-2030 (USD MILLION)
TABLE 210. ASIA-PACIFIC TRAVEL VACCINES MARKET SIZE, BY RNA AND DNA VACCINES, 2018-2030 (USD MILLION)
TABLE 211. ASIA-PACIFIC TRAVEL VACCINES MARKET SIZE, BY SUBUNIT, RECOMBINANT, POLYSACCHARIDE, AND CONJUGATE VACCINES, 2018-2030 (USD MILLION)
TABLE 212. ASIA-PACIFIC TRAVEL VACCINES MARKET SIZE, BY TOXOID VACCINES, 2018-2030 (USD MILLION)
TABLE 213. ASIA-PACIFIC TRAVEL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 214. ASIA-PACIFIC TRAVEL VACCINES MARKET SIZE, BY NASAL SPRAY VACCINES, 2018-2030 (USD MILLION)
TABLE 215. ASIA-PACIFIC TRAVEL VACCINES MARKET SIZE, BY ORAL VACCINES, 2018-2030 (USD MILLION)
TABLE 216. ASIA-PACIFIC TRAVEL VACCINES MARKET SIZE, BY PARENTERAL VACCINES, 2018-2030 (USD MILLION)
TABLE 217. ASIA-PACIFIC TRAVEL VACCINES MARKET SIZE, BY TRAVELER TYPE, 2018-2030 (USD MILLION)
TABLE 218. ASIA-PACIFIC TRAVEL VACCINES MARKET SIZE, BY STUDENT TRAVELERS, 2018-2030 (USD MILLION)
TABLE 219. ASIA-PACIFIC TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 220. ASIA-PACIFIC TRAVEL VACCINES MARKET SIZE, BY ADULT VACCINES, 2018-2030 (USD MILLION)
TABLE 221. ASIA-PACIFIC TRAVEL VACCINES MARKET SIZE, BY PEDIATRIC VACCINES, 2018-2030 (USD MILLION)
TABLE 222. ASIA-PACIFIC TRAVEL VACCINES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 223. ASIA-PACIFIC TRAVEL VACCINES MARKET SIZE, BY TECHNOLOGICAL ADVANCEMENTS, 2018-2030 (USD MILLION)
TABLE 224. ASIA-PACIFIC TRAVEL VACCINES MARKET SIZE, BY ALTERNATIVE DELIVERY SYSTEMS, 2018-2030 (USD MILLION)
TABLE 225. ASIA-PACIFIC TRAVEL VACCINES MARKET SIZE, BY NOVEL ADJUVANTS, 2018-2030 (USD MILLION)
TABLE 226. ASIA-PACIFIC TRAVEL VACCINES MARKET SIZE, BY VACCINE PRODUCTION TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 227. ASIA-PACIFIC TRAVEL VACCINES MARKET SIZE, BY PLANT-BASED PRODUCTION, 2018-2030 (USD MILLION)
TABLE 228. ASIA-PACIFIC TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 229. AUSTRALIA TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 230. AUSTRALIA TRAVEL VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
TABLE 231. AUSTRALIA TRAVEL VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINES, 2018-2030 (USD MILLION)
TABLE 232. AUSTRALIA TRAVEL VACCINES MARKET SIZE, BY RNA AND DNA VACCINES, 2018-2030 (USD MILLION)
TABLE 233. AUSTRALIA TRAVEL VACCINES MARKET SIZE, BY SUBUNIT, RECOMBINANT, POLYSACCHARIDE, AND CONJUGATE VACCINES, 2018-2030 (USD MILLION)
TABLE 234. AUSTRALIA TRAVEL VACCINES MARKET SIZE, BY TOXOID VACCINES, 2018-2030 (USD MILLION)
TABLE 235. AUSTRALIA TRAVEL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 236. AUSTRALIA TRAVEL VACCINES MARKET SIZE, BY NASAL SPRAY VACCINES, 2018-2030 (USD MILLION)
TABLE 237. AUSTRALIA TRAVEL VACCINES MARKET SIZE, BY ORAL VACCINES, 2018-2030 (USD MILLION)
TABLE 238. AUSTRALIA TRAVEL VACCINES MARKET SIZE, BY PARENTERAL VACCINES, 2018-2030 (USD MILLION)
TABLE 239. AUSTRALIA TRAVEL VACCINES MARKET SIZE, BY TRAVELER TYPE, 2018-2030 (USD MILLION)
TABLE 240. AUSTRALIA TRAVEL VACCINES MARKET SIZE, BY STUDENT TRAVELERS, 2018-2030 (USD MILLION)
TABLE 241. AUSTRALIA TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 242. AUSTRALIA TRAVEL VACCINES MARKET SIZE, BY ADULT VACCINES, 2018-2030 (USD MILLION)
TABLE 243. AUSTRALIA TRAVEL VACCINES MARKET SIZE, BY PEDIATRIC VACCINES, 2018-2030 (USD MILLION)
TABLE 244. AUSTRALIA TRAVEL VACCINES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 245. AUSTRALIA TRAVEL VACCINES MARKET SIZE, BY TECHNOLOGICAL ADVANCEMENTS, 2018-2030 (USD MILLION)
TABLE 246. AUSTRALIA TRAVEL VACCINES MARKET SIZE, BY ALTERNATIVE DELIVERY SYSTEMS, 2018-2030 (USD MILLION)
TABLE 247. AUSTRALIA TRAVEL VACCINES MARKET SIZE, BY NOVEL ADJUVANTS, 2018-2030 (USD MILLION)
TABLE 248. AUSTRALIA TRAVEL VACCINES MARKET SIZE, BY VACCINE PRODUCTION TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 249. AUSTRALIA TRAVEL VACCINES MARKET SIZE, BY PLANT-BASED PRODUCTION, 2018-2030 (USD MILLION)
TABLE 250. CHINA TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 251. CHINA TRAVEL VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
TABLE 252. CHINA TRAVEL VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINES, 2018-2030 (USD MILLION)
TABLE 253. CHINA TRAVEL VACCINES MARKET SIZE, BY RNA AND DNA VACCINES, 2018-2030 (USD MILLION)
TABLE 254. CHINA TRAVEL VACCINES MARKET SIZE, BY SUBUNIT, RECOMBINANT, POLYSACCHARIDE, AND CONJUGATE VACCINES, 2018-2030 (USD MILLION)
TABLE 255. CHINA TRAVEL VACCINES MARKET SIZE, BY TOXOID VACCINES, 2018-2030 (USD MILLION)
TABLE 256. CHINA TRAVEL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 257. CHINA TRAVEL VACCINES MARKET SIZE, BY NASAL SPRAY VACCINES, 2018-2030 (USD MILLION)
TABLE 258. CHINA TRAVEL VACCINES MARKET SIZE, BY ORAL VACCINES, 2018-2030 (USD MILLION)
TABLE 259. CHINA TRAVEL VACCINES MARKET SIZE, BY PARENTERAL VACCINES, 2018-2030 (USD MILLION)
TABLE 260. CHINA TRAVEL VACCINES MARKET SIZE, BY TRAVELER TYPE, 2018-2030 (USD MILLION)
TABLE 261. CHINA TRAVEL VACCINES MARKET SIZE, BY STUDENT TRAVELERS, 2018-2030 (USD MILLION)
TABLE 262. CHINA TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 263. CHINA TRAVEL VACCINES MARKET SIZE, BY ADULT VACCINES, 2018-2030 (USD MILLION)
TABLE 264. CHINA TRAVEL VACCINES MARKET SIZE, BY PEDIATRIC VACCINES, 2018-2030 (USD MILLION)
TABLE 265. CHINA TRAVEL VACCINES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 266. CHINA TRAVEL VACCINES MARKET SIZE, BY TECHNOLOGICAL ADVANCEMENTS, 2018-2030 (USD MILLION)
TABLE 267. CHINA TRAVEL VACCINES MARKET SIZE, BY ALTERNATIVE DELIVERY SYSTEMS, 2018-2030 (USD MILLION)
TABLE 268. CHINA TRAVEL VACCINES MARKET SIZE, BY NOVEL ADJUVANTS, 2018-2030 (USD MILLION)
TABLE 269. CHINA TRAVEL VACCINES MARKET SIZE, BY VACCINE PRODUCTION TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 270. CHINA TRAVEL VACCINES MARKET SIZE, BY PLANT-BASED PRODUCTION, 2018-2030 (USD MILLION)
TABLE 271. INDIA TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 272. INDIA TRAVEL VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
TABLE 273. INDIA TRAVEL VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINES, 2018-2030 (USD MILLION)
TABLE 274. INDIA TRAVEL VACCINES MARKET SIZE, BY RNA AND DNA VACCINES, 2018-2030 (USD MILLION)
TABLE 275. INDIA TRAVEL VACCINES MARKET SIZE, BY SUBUNIT, RECOMBINANT, POLYSACCHARIDE, AND CONJUGATE VACCINES, 2018-2030 (USD MILLION)
TABLE 276. INDIA TRAVEL VACCINES MARKET SIZE, BY TOXOID VACCINES, 2018-2030 (USD MILLION)
TABLE 277. INDIA TRAVEL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 278. INDIA TRAVEL VACCINES MARKET SIZE, BY NASAL SPRAY VACCINES, 2018-2030 (USD MILLION)
TABLE 279. INDIA TRAVEL VACCINES MARKET SIZE, BY ORAL VACCINES, 2018-2030 (USD MILLION)
TABLE 280. INDIA TRAVEL VACCINES MARKET SIZE, BY PARENTERAL VACCINES, 2018-2030 (USD MILLION)
TABLE 281. INDIA TRAVEL VACCINES MARKET SIZE, BY TRAVELER TYPE, 2018-2030 (USD MILLION)
TABLE 282. INDIA TRAVEL VACCINES MARKET SIZE, BY STUDENT TRAVELERS, 2018-2030 (USD MILLION)
TABLE 283. INDIA TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 284. INDIA TRAVEL VACCINES MARKET SIZE, BY ADULT VACCINES, 2018-2030 (USD MILLION)
TABLE 285. INDIA TRAVEL VACCINES MARKET SIZE, BY PEDIATRIC VACCINES, 2018-2030 (USD MILLION)
TABLE 286. INDIA TRAVEL VACCINES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 287. INDIA TRAVEL VACCINES MARKET SIZE, BY TECHNOLOGICAL ADVANCEMENTS, 2018-2030 (USD MILLION)
TABLE 288. INDIA TRAVEL VACCINES MARKET SIZE, BY ALTERNATIVE DELIVERY SYSTEMS, 2018-2030 (USD MILLION)
TABLE 289. INDIA TRAVEL VACCINES MARKET SIZE, BY NOVEL ADJUVANTS, 2018-2030 (USD MILLION)
TABLE 290. INDIA TRAVEL VACCINES MARKET SIZE, BY VACCINE PRODUCTION TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 291. INDIA TRAVEL VACCINES MARKET SIZE, BY PLANT-BASED PRODUCTION, 2018-2030 (USD MILLION)
TABLE 292. INDONESIA TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 293. INDONESIA TRAVEL VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
TABLE 294. INDONESIA TRAVEL VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINES, 2018-2030 (USD MILLION)
TABLE 295. INDONESIA TRAVEL VACCINES MARKET SIZE, BY RNA AND DNA VACCINES, 2018-2030 (USD MILLION)
TABLE 296. INDONESIA TRAVEL VACCINES MARKET SIZE, BY SUBUNIT, RECOMBINANT, POLYSACCHARIDE, AND CONJUGATE VACCINES, 2018-2030 (USD MILLION)
TABLE 297. INDONESIA TRAVEL VACCINES MARKET SIZE, BY TOXOID VACCINES, 2018-2030 (USD MILLION)
TABLE 298. INDONESIA TRAVEL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 299. INDONESIA TRAVEL VACCINES MARKET SIZE, BY NASAL SPRAY VACCINES, 2018-2030 (USD MILLION)
TABLE 300. INDONESIA TRAVEL VACCINES MARKET SIZE, BY ORAL VACCINES, 2018-2030 (USD MILLION)
TABLE 301. INDONESIA TRAVEL VACCINES MARKET SIZE, BY PARENTERAL VACCINES, 2018-2030 (USD MILLION)
TABLE 302. INDONESIA TRAVEL VACCINES MARKET SIZE, BY TRAVELER TYPE, 2018-2030 (USD MILLION)
TABLE 303. INDONESIA TRAVEL VACCINES MARKET SIZE, BY STUDENT TRAVELERS, 2018-2030 (USD MILLION)
TABLE 304. INDONESIA TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 305. INDONESIA TRAVEL VACCINES MARKET SIZE, BY ADULT VACCINES, 2018-2030 (USD MILLION)
TABLE 306. INDONESIA TRAVEL VACCINES MARKET SIZE, BY PEDIATRIC VACCINES, 2018-2030 (USD MILLION)
TABLE 307. INDONESIA TRAVEL VACCINES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 308. INDONESIA TRAVEL VACCINES MARKET SIZE, BY TECHNOLOGICAL ADVANCEMENTS, 2018-2030 (USD MILLION)
TABLE 309. INDONESIA TRAVEL VACCINES MARKET SIZE, BY ALTERNATIVE DELIVERY SYSTEMS, 2018-2030 (USD MILLION)
TABLE 310. INDONESIA TRAVEL VACCINES MARKET SIZE, BY NOVEL ADJUVANTS, 2018-2030 (USD MILLION)
TABLE 311. INDONESIA TRAVEL VACCINES MARKET SIZE, BY VACCINE PRODUCTION TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 312. INDONESIA TRAVEL VACCINES MARKET SIZE, BY PLANT-BASED PRODUCTION, 2018-2030 (USD MILLION)
TABLE 313. JAPAN TRAVEL VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 314. JAPAN TRAVEL VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
TABLE 315. JAPAN TRAVEL VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINES, 2018-2030 (USD MILLION)
TABLE 316. JAPAN TRAVEL VACCINES MARKET SIZE, BY RNA AND DNA VACCINES, 2018-2030 (USD MILLION)
TABLE 317. JAPAN TRAVEL VACCINES MARKET SIZE, BY SUBUNIT, RECOMBINANT, POLYSACCHARIDE, AND CONJUGATE VACCINES, 2018-2030 (USD MILLION)
TABLE 318. JAPAN TRAVEL VACCINES MARKET SIZE, BY TOXOID VACCINES, 2018-2030 (USD MILLION)
TABLE 319. JAPAN TRAVEL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 320. JAPAN TRAVEL VACCINES MARKET SIZE, BY NASAL SPRAY VACCINES, 2018-2030 (USD MILLION)
TABLE 321. JAPAN TRAVEL VACCINES MARKET SIZE, BY ORAL VACCINES, 2018-2030 (USD MILLION)
TABLE 322. JAPAN TRAVEL VACCINES MARKET SIZE, BY PARENTERAL VACCINES, 2018-2030 (USD MILLION)
TABLE 323. JAPAN TRAVEL VACCINES MARKET SIZE, BY TRAVELER TYPE, 2018-2030 (USD MILLION)
TABLE 324. JAPAN TRAVEL VACCINES MARKET SIZE, BY STUDENT TRAVELERS, 2018-2030 (USD MILLION)
TABLE 325. JAPAN TRAVEL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 326. JAPAN TRAVEL VACCINES MARKET SIZE, BY ADULT VACCINES, 2018-2030 (USD MILLION)
TABLE 327. JAPAN TRAVEL VACCINES MARKET SIZE, BY PEDIATRIC VACCINES, 2018-2030 (USD MILLION)
TABLE 328. JAPAN TRAVEL VACCINES MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 329. JAPAN TRAVEL VACCINES MARKET SIZE, BY TECHNOLOGICAL ADVANCEMENTS, 2018-2030 (USD MILLION)
TABLE 330. JAPAN TRAVEL VACCINES MARKET SIZE, BY ALTERNATIVE DELIVERY SYSTEMS, 2018-2030 (USD MILLION)
TABLE 331. JAPAN TRAVEL VACCINES MARKET SIZE, BY NOVEL ADJUVANTS, 2018-2030 (USD MILLION)
TABLE 332. JAPAN TRAVEL VACCINES MARKET SIZE, BY VACCINE PRODUCTION TECHNOLOGIES, 2018-2030 (USD

Companies Mentioned

  • Abbott Laboratories
  • AstraZeneca PLC
  • Bavarian Nordic A/S
  • Bharat Biotech Ltd.
  • Bio-Manguinhos
  • Bio-Med (P) Limited
  • Biological E Limited
  • Cadila Pharmaceuticals Limited
  • CSL Limited
  • Dano Vaccines & Biologicals Private Limited
  • Dynavax Technologies Corporation
  • Emergent BioSolutions Inc.
  • GlaxoSmithKline PLC
  • Incepta Pharmaceuticals Ltd.
  • Indian Immunologicals Ltd.
  • Johnson & Johnson Services, Inc
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Serum Institute of India Pvt. Ltd.
  • Shenzhen Kangtai Biological Products Co., Ltd.
  • Takeda Pharmaceutical Company Limited
  • Valneva SE
  • Walvax Biotechnology Co., Ltd.

Methodology

Loading
LOADING...

Related Topics

Related Reports

Adult Vaccines Market by Vaccine Type, Disease Indication, End User - Global Forecast 2025-2030 - Product Image

Adult Vaccines Market by Vaccine Type, Disease Indication, End User - Global Forecast 2025-2030

  • Report
  • 198 Pages
  • Global
From
Preventive Vaccine Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

Preventive Vaccine Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 150 Pages
  • Global
From
Preventable Vaccines - Global Strategic Business Report - Product Image

Preventable Vaccines - Global Strategic Business Report

  • Report
  • 391 Pages
  • Global
From
Travel Vaccines Market Report 2025 - Product Image

Travel Vaccines Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Cholera Vaccines Market by Type, Method of Administration, End User, Age Group - Global Forecast 2025-2030 - Product Image

Cholera Vaccines Market by Type, Method of Administration, End User, Age Group - Global Forecast 2025-2030

  • Report
  • 199 Pages
  • Global
From

About the Market

The Travel Vaccine market is a subset of the Vaccine market, focusing on vaccines that are recommended for travelers. These vaccines are typically recommended for those who are traveling to areas with a higher risk of certain diseases, such as yellow fever, typhoid, and hepatitis A and B. Travel vaccines are typically administered by a healthcare provider, and may require multiple doses over a period of time. The Travel Vaccine market is a growing sector, with an increasing number of travelers seeking protection from diseases that may be present in their destination countries. Vaccines are also becoming more widely available, with many countries now offering travel vaccines as part of their public health programs. Some companies in the Travel Vaccine market include Sanofi Pasteur, GlaxoSmithKline, Merck, Pfizer, and Novartis. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.